Expression of bFGF and VEGF in acute leukemia and its effects on HL-60 cell growth.
- Author:
Wei-Ping ZHANG
1
;
Xie-Qun CHUN
;
Yong-Qing ZHANG
;
Rong LIANG
;
Ya-Hong LI
;
Guang-Xue GAO
;
Hua-Feng ZHU
Author Information
1. Department of Hematology, Xijing Hospital, The Fourth Military Medical University, Xi'an 710032, China.
- Publication Type:Journal Article
- MeSH:
Acute Disease;
Adolescent;
Adult;
Aged;
Cell Line, Tumor;
Cell Proliferation;
Cell Survival;
drug effects;
Child;
Culture Media, Conditioned;
metabolism;
Dose-Response Relationship, Drug;
Female;
Fibroblast Growth Factor 2;
blood;
genetics;
metabolism;
HL-60 Cells;
Humans;
Leukemia;
blood;
pathology;
Male;
Middle Aged;
Oligoribonucleotides, Antisense;
pharmacology;
U937 Cells;
Vascular Endothelial Growth Factor A;
blood;
genetics;
metabolism
- From:
Journal of Experimental Hematology
2005;13(1):91-94
- CountryChina
- Language:Chinese
-
Abstract:
The study was to investigate the expression levels of basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) in the serum of patients with acute leukemia and supernatants of leukemia cell lines as well as effects of VEGF-specific antisense oligodeoxynucleotides (ASODN) on the growth of HL-60 cells. Meanwhile the methods to evaluate the VEGF level in the serum of patients with acute leukemia were explored. The levels of bFGF and VEGF in the serum from 32 patients with acute leukemia and 10 healthy subjects and in the supernatants of 5 various human leukemia cell lines were quantified by means of the enzyme-linked immunosorbent assay (ELISA) and were compared. VEGF levels were evaluated not only without standardization but also after standardized by platelet and finally expressed as VEGF/PLT (pg/10(6)). After with different concentrations of VEGF ASODN, HL-60 cell viability was examined with MTT assay and VEGF levels in supernatants were measured with ELISA, respectively. The results showed that bFGF was detected (3 pg/ml) in 14 out of 32 serum samples from patients with acute leukemia, and the positive (37.5%) was significantly higher than that in healthy controls (10%) (P < 0.01). 3 out of 5 supernanant samples obtained from leukemia cell lines demonstrated positive for bFGF as well. There is no difference of the serum VEGF levels between leukemia patients and healthy controls, but the serum VEGF levels in the serum from leukemia patients were significantly higher than those in healthy controls (P < 0.05) after standardization. 4 out of 5 leukemia cell (U937 excluded) were found to express VEGF in the supernanant. After exposure of HL-60 cells to VEGF ASODN at a concentration of 0.5, 1 and 5 micromol/L for 24 hours, the cell viability gradually dropped down to lower levels (P < 0.05 vs controls). After treatment of HL-60 cells with VEGF ASODN at a concentration of 1, 5 and 20 micromol/L for 24 hours, the VEGF levels in supernatants of target cells decreased (P < 0.05 vs controls). The patients with acute leukemia represented the higher levels of serum bFGF and VEGF than controls. Most of leukemia cell lines expressed bFGF and VEGF at different levels. It is concluded that bFGF and VEGF both have effects on regulations of angiogenesis in acute leukemia, but VEGF plays a pivotal role. VEGF-specific ASODN may have a role in them VEGF expression downregulated. Different results may be obtained in the evaluation of VEGF levels in the serum of patients with acute leukemia if different calculation methods are used. The methods reported can measure leukemia associated VEGF more accurately.
